The Fleming Fund commits £1m to improving the detection of substandard and falsified medicines

The Fleming Fund is delighted to announce a new £1m investment to the Foundation for Innovative New Diagnostics (FIND) to improve the identification of substandard and falsified medicines.

Substandard and falsified (SF) medicines are a major cause of growing drug-resistance in a number of diseases. Therefore, finding technologies that can detect these medicines can help reduce this risk. The presence of SF medical products in countries, and their use by patients, impacts our ability to effectively tackle antimicrobial resistance (AMR). Further investigation of SF medicine use is needed, both to understand the true scale of AMR as well as, how much they may be contributing to the growing resistance.

Many low- and middle-income countries (LMICs) do not have access to central laboratory facilities that can test the quality of medicines. Therefore, field-based screening technologies offer the opportunity for LMICs to be better able to tackle the SF medicines and AMR.

For this reason, the Fleming Fund is investing in FIND to undertake an assessment of the current practices for identification and run a pilot evaluation study of field-based screening technologies in Laos.

This new investment compliments the current Fleming Fund grant to the World Health Organisation (WHO) on addressing the global challenge of SF medicines. Through improving surveillance and detection of SF medicines, it is possible to optimise the use of medicines and in turn reduce the threat of AMR.

More Like This

There is a growing recognition that both sex (the physical dimension) and gender (the psychosocial dimension) – and the interaction between them and behaviours between them – can play a significant role in antimicrobial resistance (AMR) and use (AMU).

Following the publication of our [Phase I Report]( on Tuesday 26th April, the Fleming Fund hosted a launch event the following Wednesday. The aim of the launch event was to announce HMG approval for the Fleming Fund until 2025, showcase our new publication and share our partners’ work.